Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis

Abstract

Get full access to this article

View all access options for this article.

References

Hauser

Waubant

Arnold

Vollmer

Antel

Fox

. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.

Roll

Arumugam

Kneitz

Dorner

Hans-Peter

. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2377–2386.

Carson

Evens

Richey

Habermann

Focosi

Seymour

. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project. Blood 2009; 14: 4834–4840.

Fleischmann

. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient withrheumatoid arthritis. Arthritis Rheum 2009; 60: 3225–3228.

Clifford

Ances

Costello

Rosen-Schmidt

Andersson

Parks

. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; [ePub ahead of print].

Bar-Or

Calabresi

Arnold

Markowitz

Shafer

Kasper

. Rituximab in relapsing–remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol 2008; 63: 395–400.

Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH). Guideline for industry: Dose-response information to support drug registration. Federal Register 1994; 59:55972–55976. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073115.pdf.